Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Dezima Pharma Appoints Seasoned New CEO

Published: Thursday, June 13, 2013
Last Updated: Wednesday, June 12, 2013
Bookmark and Share
Appointment of Rob de Ree as Company’s new Chief Executive Officer.

Dezima Pharma has announced that it has appointed Rob de Ree as its new Chief Executive Officer.

Mr. de Ree has over 20 years of experience in sales & marketing, business development and general management in Pharma and Medtech, including Medtronic, Crucell and the cardiovascular franchise of Byk Gulden.

Most recently he held the CEO position at Amsterdam-based cardiovascular monitoring company, BMEYE BV, which was successfully sold to Edwards Lifesciences in 2012 under his leadership. He holds a degree in Pharmacy.

Dezima was founded in 2012 by Prof. John Kastelein, Professor of Medicine at the Department of Vascular Medicine at the Academic Medical Center of the University of Amsterdam, and focuses on the development of novel products to treat dyslipidemic patients suffering from cardiovascular disease.

Its lead program involves the development of the CETP inhibitor DEZ-001 (previously TA-8995) which was in-licensed from Mitsubishi Tanabe Pharma Corporation.

The Company has recently raised a total of €14.2 million and is fully financed to execute a phase III enabling study in dyslipidemia. This phase II study “TULIP” is scheduled to start in Q3 2013.

Mr. de Ree commented, “The treatment of dyslipidemia requires novel drugs to further improve patient care. Dezima’s ambition is to seek new solutions to treat this disease, of which our lead program, DEZ-001, a CETP inhibitor, is a potential best-in-class. This is a great opportunity for me to take on the role of CEO of Dezima and to work with such an experienced team.”

Managing Partner of Forbion and Chairman of Dezima’s board, Sander Slootweg added, "Rob brings a wealth of experience to Dezima as he knows the cardiovascular field inside out. Besides his operational strength, Rob will also spearhead our business development activities as we have the only later-stage, unencumbered asset in a commercially attractive field, the evolving CETP space.”

Mr. de Ree is taking over from Dezima’s interim CEO and General Partner of Forbion Capital Partners, Sander van Deventer, who has stepped down from the role, but will remain closely involved with the Company by joining the Scientific Advisory Board (SAB).

The SAB also includes world-leading experts in the dyslipidemia space such as Dr Philip Barter, Professor at The Heart Research Institute, Sydney, Australia, and Dr Bryan Brewer, Senior Research Consultant of Lipoprotein and Atherosclerosis Research at the Medstar Research Institute, Washington DC, USA.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Dezima Reports Positive Results in its Phase 2b TULIP Trial
Combines outstanding efficacy and safety profile with favourable pharmacokinetics.
Saturday, August 30, 2014
Dezima Extends Clinical Development Program for its CETP Inhibitor TA-8995
Phase 2b TULIP study readout in August 2014, new Lipoprotein(a) study approved.
Thursday, July 10, 2014
Dezima Completes Patient Enrolment for TULIP Phase 2b Study
Aim of the study is to investigate the effects of TA-8995 in mild dyslipidemia patients.
Monday, January 13, 2014
Dezima Initiates Phase 2b TULIP Study on CETP Inhibitor Program DEZ-001
TULIP study will investigate the effects of different doses of DEZ-001 on CVD biomarkers.
Friday, August 30, 2013
Dezima In-Licenses CETP Inhibitor Program from MTPC
World-renowned dyslipidemia experts join Dezima’s Scientific Advisory Board.
Thursday, April 25, 2013
Scientific News
How Skeletal Stem Cells Form The Blueprint Of The Face
USC researchers discover that two types of molecular signals work to control where and when stem cells turn into facial cartilage.
Ketamine Metabolism Lifts Depression
NIH-funded team finds rapid-acting, non-addicting agent in mouse study.
Faster, Cheaper Way to Produce New Antibiotics
A novel way of synthesising a promising new antibiotic has been identified by scientists at the University of Bristol.
Process Contaminants in Vegetable Oils and Foods
Glycerol-based process contaminants found in palm oil, but also in other vegetable oils, margarines and some processed foods, raise potential health concerns for average consumers of these foods in all young age groups, and for high consumers in all age groups.
Improving Natural Killer Cancer Therapy
Vanderbilt University researchers discover transcription factor critical for NK cell expansion. Findings could lead to increased therapeutic efficacy.
Molecular Mechanism For Generating Specific Antibody Responses Discovered
Study could spur more ways to treat autoimmune disease, develop accurate vaccines.
Monovar Drills Down Into Cancer Genome
Rice, MD Anderson develop program to ID mutations in single cancer cells.
It’s Now Easier To Go With The Flow
Rice University tool simplifies comparison of flow cytometry data for laboratories.
Autism, Cancer Share a Remarkable Number of Risk Genes
Researchers with the UC Davis Comprehensive Cancer Center, MIND Institute identify more than 40 common genes.
Number Of Known Genetic Risk Factors For Endometrial Cancer Doubled
An international collaboration of researchers has identified five new gene regions that increase a woman’s risk of developing endometrial cancer, one of the most common cancers to affect women, taking the number of known gene regions associated with the disease to nine.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!